DSM-Firmenich has delivered a strong 39.6% gain year to date, which naturally raises a question for anyone looking at the stock today. Are the cash flows that the business can generate over time enough to support the current share price around €96.10 when viewed through a Discounted Cash Flow (DCF) lens?
-
The 39.6% move so far in 2026 has lifted expectations and puts more weight on whether DSM-Firmenich's cash generation can keep up with the market's enthusiasm.
-
Recent work on its CORNEOCARE 2.0 platform in Beauty & Care points to ongoing investment in product science that may support future pricing power and cash flow durability if it gains traction with skin care customers.
-
If you'd rather focus on earnings, this one's for you. See why DSM-Firmenich's 73.3x P/E tells a different valuation story .
The stock's next move may depend on whether the intrinsic value suggested by its cash flows can comfortably support where DSM-Firmenich is trading today.
If you are weighing whether DSM-Firmenich's recent 39.6% year to date gain is supported by its cash flows, it can help to compare that question across 192 high quality undervalued stocks .
Does DSM-Firmenich Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) model here estimates what DSM-Firmenich might be worth based on the cash it can return to shareholders over time. The framework uses a 2 Stage Free Cash Flow to Equity approach and starts from latest twelve month free cash flow of about €910.8 million, which anchors the analysis in the current earning power of the business rather than in headline earnings.
Projected free cash flow is assumed to be growing over the coming decade, including an analyst view of €1,368 million by 2030, with later years based on more moderate percentage increases. That pattern points to a maturing but still expanding cash engine rather than a turnaround story. Despite the recent attention on its CORNEOCARE 2.0 work in Beauty & Care, which may influence how investors think about future skin care opportunities, the DCF projections currently put DSM-Firmenich's estimated intrinsic value substantially above the current share price of €96.10. Find out what DSM-Firmenich could be worth using our Discounted Cash Flow (DCF) estimate .
The DSM-Firmenich Narrative: What Would Justify Today's Price?
Narratives on Simply Wall St are designed to help you see what future path would need to play out in DSM-Firmenich's growth, margins and earnings for the stock to be worth significantly more or less than it is today. They sit on the Community page. Where a single valuation output gives you one number, these scenarios spell out the future it relies on so you can monitor over time whether that picture is still holding up for DSM-Firmenich.
Community views on DSM-Firmenich are split between investors who think the re-rating still has room to run and those who see most of the upside already priced in.
Bull case: 18% undervalued
"The company's breakthrough investments in biotech, fermentation, and precision nutrition are generating highly differentiated, IP-rich product introductions…"
Discover why this Narrative puts DSM-Firmenich at 18% undervalued .
Bear case: roughly fairly valued
"Despite declared synergy achievements post-merger, a significant proportion of reported EBITDA improvement is from temporary factors like force majeure in vitamins or one-off synergies…"
Explore why this Narrative puts DSM-Firmenich at roughly fairly valued .
Before acting on DSM-Firmenich's valuation, there is one more piece to check
The cash flow story for DSM-Firmenich only goes so far without looking at who is steering the business, how their incentives are set, and whether those rewards truly align with your interests. See who runs DSM-Firmenich and how they are paid .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include DSFIR.AS .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
